Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Angiogenesis is crucial for solid tumor growth, with antiangiogenic therapies effective in preclinical models.
• Human antiangiogenic therapy demonstrates limited tumor regression and survival benefits.
• Urinary cancers (renal, prostate, bladder) with advanced refractory disease are candidates for antiangiogenic therapy due to resistance to conventional treatments.

Purpose of the Study:

• To summarize unique molecular mechanisms driving angiogenesis in urinary cancers.
• To review clinical trial results of antiangiogenic therapy for these specific cancers.
• To discuss the prospects and challenges of antiangiogenic therapy in urinary oncology.

Main Methods:

• Literature review of preclinical and clinical studies on angiogenesis in urinary cancers.
• Analysis of molecular mechanisms underlying angiogenesis in renal cell, prostate, and bladder cancers.
• Synthesis of data from clinical trials investigating antiangiogenic agents.

Main Results:

• Preclinical antiangiogenic therapy shows efficacy, but human trials reveal minimal impact on tumor regression and survival.
• Urinary cancers exhibit distinct molecular pathways that promote angiogenesis.
• Clinical trials present a mixed picture, highlighting the need for further investigation.

Conclusions:

• Antiangiogenic therapy faces challenges in human urinary cancers despite preclinical success.
• Understanding unique molecular mechanisms is key to improving therapeutic strategies.
• Further research is needed to optimize antiangiogenic approaches for advanced refractory urinary cancers.